Faecal Microbiota Transplantation Reduces Lesion Severity and Medication Use in Canine Atopic Dermatitis: A Randomised, Placebo-Controlled, Double-Blinded Clinical Trial - PubMed
2 hours ago
- #faecal microbiota transplantation
- #clinical trial
- #canine atopic dermatitis
- Faecal microbiota transplantation (FMT) was tested as an adjunctive therapy for canine atopic dermatitis (cAD).
- In a randomized, placebo-controlled, double-blinded trial, 46 dogs with cAD were enrolled; 40 completed the study.
- FMT treatment involved daily oral lyophilised capsules and three monthly rectal administrations over 90 days.
- Clinical outcomes showed FMT significantly reduced lesion severity scores (CADESI-04) at months 2 and 3 compared to placebo.
- FMT also led to lower medication scores at months 2 and 3, indicating reduced symptomatic medication use.
- Sustained responders with ≥50% improvement in CADESI-04 were more frequent in the FMT group (35% vs. 5%).
- Owner Global Assessment of Treatment Efficacy favored FMT, and the therapy was well-tolerated with no significant safety issues.
- The study concludes that adjunctive FMT is a safe and effective microbiome-based add-on therapy for reducing lesion severity and medication needs in cAD.